40
Participants
Start Date
January 1, 2018
Primary Completion Date
March 31, 2021
Study Completion Date
May 31, 2021
Apixaban Oral Tablet [Eliquis]
Apixaban 5 mg BID for 3 months. Apixaban 2.5-mg BID doses will be used in a subset of patients with two or more of the following criteria: an age of at least 80 years, a body weight of no more than 60 kg, or a serum creatinine level of 1.5 mg per deciliter (133 μmol per liter) or more. Patients with advanced renal failure (CrCl between 15 ml/min and 29 mi/min) will also receive 2.5 mg BID.
Warfarin
Dose-adjusted warfarin to achieve a target international normalized ratio (INR) of 2.0 to 3.0 for 3 months
Hadassah Medical Organization, Jerusalem
Hadassah Medical Organization
OTHER